Page 12 - Clinical Development Program News Today

Daiichi Sankyo Company, Limited: DESTINY-CRC02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer Interstitial Lung Disease Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate ...

Published: Mar 16, 2021 NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23 rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics’ development programs in Galactosemia, SORD Deficie...

DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered

Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer ii 80% (n=64) CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response i Includes patients with =1 postbaseline scan or who discontinued treatment. ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs to...

Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society January 27, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU ® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister’s Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Soc...

Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Ministers Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Ministers Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with th...

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved. We use cookies to enhance your visit, personalise our content, social media features, ads & to analyse our traffic. You c...

Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer January 20, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer...

Search jobs 18-Jan-2021 ADDING MULTIMEDIA — ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in...

Hits: 1063 First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO, Japan & MUNICH, Germany & BASKING RIDGE, NJ USA I January 15, 2021 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior...